Internet Archive Scholar

Real Life Comparison of Afatinib and Erlotinib in Non-small Cell Lung Cancer With Rare EGFR Exon 18 and Exon 20 Mutations: a Turkish Oncology Group (TOG) Study [post]

Pınar Gürsoy, Ali Murat Tatlı, Dilek Erdem, Erdem Goker, Emir Çelik, Nebi Serkan Demirci, Abdullah Sakin, Muhammed Mustafa Atçı, Ertuğrul Bayram, Tuğba Akın Telli, Burak Bilgin, Ahmet Bilici (+29 others)
2021 unpublished

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (665.4 kB)
https://web.archive.org/web/20220122112044/https://assets.researchsquare.com/files/rs-1125056/v1/03701e3f-e90d-4f4e-9ff6-8f6c30cd1d27.pdf?c=1639169957

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL. The file type is application/pdf.

Objectives To compare the survival of first- and second-generation tyrosine kinase inhibitors (TKIs) in patients with rare EGFR exon 18 and exon 20 mutation-positive non-small cell lung cancer (NSCLC).Materials and Methods We retrospectively evaluated survival characteristics of 125 patients with EGFR exon 18 and exon 20 mutated NSCLC who received erlotinib or afatinib as first line treatment between 2012 and 2021 from 34 oncology centres. Since exon 20 insertion is associated with TKI
more » ... e, these 18 patients were excluded from the study.Results EGFR exon 18 mutations were seen in 60%, exon 20 mutations in 16%, and complex mutations in 24% of the patients with NSCLC who were evaluated for the study. There were 75 patients in erlotinib treated arm and 50 patients in afatinib arm. Patients treated with erlotinib had progression-free survival time (PFS) of 8.0 months and PFS was 7.0 months in the afatinib arm (p=0.869), while overall survival time (OS) was 20.0 vs 24.8 months, respectively (p=0.190). PFS of exon 18 mutated arm was 7.0 months, exon 20 mutated arm was 4.3 months, and complex mutation positive group was 17.3 months, and this was statistically significant (p=0.036). The longest OS was 32.5 months, seen in the complex mutations group, which was not statistically different than exon 18 and in exon 20 mutated groups (21.0 and 21.2 months, respectively) (p=0.323).Conclusion In this patient group, especially patients with complex mutations are as sensitive to EGFR TKI treatment similar to classical mutations, and in patients with rare exon 18 and exon 20 EGFR mutation both first- and second-generation EGFR-TKIs should be considered, especially as first- and second-line options.
doi:10.21203/rs.3.rs-1125056/v1 fatcat:yabxu6rzufffbhsjaha3t4dl2y
Open Access
Citation

Pınar Gürsoy, Ali Murat Tatlı, Dilek Erdem, Erdem Goker, Emir Çelik, Nebi Serkan Demirci, Abdullah Sakin, Muhammed Mustafa Atçı, Ertuğrul Bayram, Tuğba Akın Telli, Burak Bilgin, Ahmet Bilici, Baran Akagündüz, Sevinç Ballı, Ahmet Demirkazık, Fatıh Selcukbiricik, Serkan Menekşe, Eyyup Cavdar, Akın Öztürk, Esma Türkmen Bekmez, Serdal Turhal, Saadettin Kılıçkap, Hasan Çağrı Yıldırım, Başak Oyan, Asude Aksoy, Fatma Paksoy TURKOZ, Engin Kut, Nuran Katgı, Teoman Sakalar, Murat Akyol, Halil İbrahim Ellez, Atakan Topcu, Atike Pınar Erdoğan, Kezban Nur Pilancı, Engin Hedem, Hacı Arak, Nadiye Akdeniz, Özkan Alan, Burcu Yapar, Deniz Nart, Perran Fulden Yumuk. "Real Life Comparison of Afatinib and Erlotinib in Non-small Cell Lung Cancer With Rare EGFR Exon 18 and Exon 20 Mutations: a Turkish Oncology Group (TOG) Study." (2021)